The Brighton Collaboration: Addressing the need for standardized case definitions of adverse events following immunization (AEFI)

Vaccine

Volumn 21, Issue 3-4, 2002, Pages 298-302

  Bonhoeffer, Jan ^a   Kohl, Katrin ^b   Chen, Robert ^b   Duclos, Philippe ^c   Heijbel, Harald ^d   Heininger, Ulrich ^a   Jefferson, Tom ^e   Loupi, Elisabeth ^f  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^e Cochrane Vaccines Field and Health Reviews Ltd ^*  (Italy)

^f SANOFI PASTEUR   (France)

Author keywords

AEFI; Case definition; Immunization; Safety; Standardization

Indexed keywords

ARTICLE; DEVELOPED COUNTRY; DEVELOPING COUNTRY; EVALUATION; HEALTH SURVEY; IMMUNIZATION; INFORMATION PROCESSING; INTERNET; MEDICAL RESEARCH; METHODOLOGY; ORGANIZATION; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; SAFETY; SCIENTIFIC LITERATURE; STANDARDIZATION; VOLUNTEER; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG SURVEILLANCE PROGRAM; HEALTH; HUMAN; ORGANIZATION AND MANAGEMENT; PREVENTIVE HEALTH SERVICE; STANDARD; VACCINATION;

VACCINE;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CLINICAL TRIALS; DATA COLLECTION; HUMANS; IMMUNIZATION PROGRAMS; PRACTICE GUIDELINES; REFERENCE STANDARDS; SAFETY; VACCINATION; VACCINES; VACCINES, COMBINED; WORLD HEALTH;

EID: 0037073585     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00449-8     Document Type: Article

References (32)

1. Fescharek R., Nicolay U., Arras-Reiter C. Monitoring and safety assessment in phase I to II clinical trials. Dev. Biol. Stand. 95:1998;203-220.
2. The Uppsala Monitoring Centre. WHO Collaborating Centre for International Drug Monitoring: Adverse Reaction Terminology (WHO-ART). Available at: http://www.who-umc.org/pdfs/ardguide.pdf.
3. International Conference on Harmonization. The Medical Dictionary for Regulatory Activities. Available at: http://www.ifpma.org/ichMedDRA.html
4. Braun M, Terracino G, Salive, et al. Report of a US Public Health Service Workshop on HHE after pertussis immunisation. Pediatrics 1998;102:e52.
5. King G., Markowitz L., Heath J., Redd S., Coleman S., Bellini J.et al. Antibody response to Measels-Mumps-Rubella vaccine of children with mild illness at the time of vaccination. JAMA. 275:1996;704-707.
6. Shinefield H., Black S., Staele B.et al. Safety, tolerability and immunogenicity of concomitant injections in separate locations of MMRII, Varivax and Tetramune in healthy children vs. concomitant injections of MMR II and Tetramune followed 6 weeks later by Varivax. Pediatr. Infect. Dis. J. 7:1998;980-985.
7. Usonis V., Bakasenas V., Kaufhold A.et al. Reactogenicity and immunogenicity of a new live attenuated combined Measles, Mumps and Rubella vaccine in healthy children. Pediatr. Infect. Dis. J. 18:1999;42-48.
8. Klinge J., Lugauer S., Korn K.et al. Comparison of immunogenicity and reactogenicity of a measles vaccinated at 9-11, 12-14 or 15-17 months of age, Mumps and Rubella (MMR) vaccine in German children. Vaccine. 18:2000;3134-3140.
9. Crovari P., Gabutti G., Giamanco G.et al. The cooperative group for the study of MMR vaccines. Reactogenicity and immunogenicity of a new combined Measels-Mumps-Rubella vaccine: results of a multicenter trial. Vaccine. 18:2000;2796-2803.
10. Gustafsson L., Hallander H., Olin P.et al. A controlled trial of a two component acellular, a five component acellular and a whole-cell pertussis vaccine. N. Engl. J. Med. 334:1996;349-355.
11. Schmitt H.J., Schuind A., Knuf M.et al. Clinical experience of a tricomponent acellular pertussis vaccine combined with diphteria and tetanus toxoids for primary vaccination in 22,505 infants. J. Pediatr. 129:1996;695-701.
12. Liese J., Meschievitz C., Harzer E.et al. Efficacy of a two-component acellular pertussis vaccine in infants. PIDJ. 16:1997;1038-1044.
13. Schmitt-Grohé S., Stehr K., Cherry J.D., Heininger U.et al. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP(DTaP) vaccine, the Lederle whole cell component DTP (DTP) or DT vaccine. Dev. Biol. Stand. 89:1997;113-118.
14. Simondon F., Preziosi M., Yam A.et al. A randomized double blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine. 15:1997;1606-1612.
15. Ramkissoon A., Coovadia H.M., Loening W.E.K.et al. Does whole-cell pertussis vaccine protect black South African infants. South African Med. J. 79:1991;645-649.
16. Blumberg D.A., Lewis K., Mink C.A.M.et al. Severe reactions associated with Diphtheria-Tetanus-Pertussis vaccine: detailed study of children with seizures, hypotonic-hyporesponsive episodes, high fevers, and persistent crying. Pediatrics. 91:1993;1158-1165.
17. Cody C.L., Baraff L.J., Cherry J.D.et al. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics. 68:1981;650-660.
18. Greco D., Salmaso S., Mastrantonio P., Guiliano M., Tozzi A., Anemona A.et al. Progretto Pertosse Working Group: a controlled trial of two acellular vaccines and one whole cell vaccine against pertussis. N. Engl. J. Med. 334:1996;341-348.
19. Gold R., Scheifele D., Halperin S., Dery P.et al. Hypotonic-hyporesponsive episodes in children hospitalized at 10 Canadian Pediatric Tertiary-Care Centers, 1991-1994. Can. Commun. Dis. Rep. 23:1997;73-76.
20. Überall M.A., Stehr K., Cherry J.D.et al. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis componentDTP(DTaP vaccine, the Lederle whole cell component DTP (DTP) or DT vaccine. Dev. Biol. Stand. 89:1997;83-89.
21. Olin P., Rasmussen F., Gustafsson L.et al. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Lancet. 350:1997;1569-1577.
22. Mills E., Gold R., Thipphawong J.et al. Safety and immunogenicity of a combined five component pertussis diphtheria-tetanus-inactivated poliomyelitis-Haemophilus b conjugate vaccine administered to infants at 2, 4 and 6 months of age. Vaccine. 16:1998;576-585.
23. Goodwin H., Nash M., Gold M., Heath T.C., Burgess M.A. Vaccination of children following a previous hypotonic-hyporesponsive episode. J. Paediatr. Child Health. 35:1999;549-552.
24. Gold M., Goodwin H., Botham S.et al. Revaccination of 421 children with a past history of an adverse vaccine reaction in a special immunization service. Arch. Dis. Child. 83:2000;128-131.
25. Vermeer-de Bondt P.E., Labadie J., Rümke H.C. Rate of recurrent collapse after vaccination with whole cell pertussis vaccine: follow up study. BMJ. 316:1998;902-903.
26. Zanardi L.R., Haber P., Mootrey G.T.et al. Intussusception among recipients of rotavirus vaccine: reports to the vaccine adverse event reporting system. Pediatrics. 107:2001;E97.
27. Murphy T.V., Gargiullo P.M., Massoudi M.S.et al. Intussusception among infants given an oral rotavirus vaccine. N. Engl. J. Med. 344:2001;564-572.
28. Kramarz P., France E.K., Destefano F.et al. Population-based study of rotavirus vaccination and intussusception. Pediatr. Infect. Dis. J. 20:2001;410-416.
29. Susan S. Ellenberg. Safety Considerations for New Vaccine Development. FDA Workshop on Evaluation of New Vaccines. November, 2000. http://www.fda.gov/cber/summaries/111400se.htm.
30. Jacobson R.M., Adegbenro A., Pankratz V.S.et al. Adverse events and vaccination-the lack of power and predictability of infrequent events in pre-licensure study. Vaccine. 19:2001;2428-2433.
31. Chen R.T. Vaccine risks: real, perceived, and unknown. Vaccine. 17:1999;S41-46.
32. Chen R.T., Rastogi S.C., Mullen J.R., Hayes S.W., Cochi S.L., Donlon J.A.et al. The Vaccine Adverse Event Reporting System (VAERS). Vaccine. 12:1994;542-550.